INSP
Inspire Medical Systems, Inc.
$51.76
+0.24
(+0.47%)
Mkt Cap
1.49B
Volume
1,052,358
52W Range
38.91-147.03
Sector
Healthcare
Beta
0.71
EPS (TTM)
4.53
P/E Ratio
11.43
Revenue (TTM)
915.25M
Rev Growth (5Y)
+51.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$21.19
Overvalued
strong signal
144.3% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 911.98M | 802.80M | 624.80M | 407.86M | 233.39M | 115.38M | 82.05M | 50.59M | 28.57M | 16.43M | 8.01M |
| Net Income | 145.42M | 53.51M | (21.15M) | (44.88M) | (42.04M) | (57.20M) | (33.24M) | (21.83M) | (17.51M) | (18.53M) | (21.34M) |
| EPS | 4.95 | 1.80 | -0.72 | -1.60 | -1.54 | -2.19 | -1.40 | -1.50 | -1.30 | -1.49 | -1.71 |
| Free Cash Flow | 78.48M | 91.12M | 1.02M | 2.47M | (24.79M) | (55.50M) | (35.59M) | (18.94M) | (16.20M) | (18.25M) | (22.60M) |
| FCF / Share | 2.67 | 3.06 | 0.03 | 0.09 | -0.91 | -2.13 | -1.49 | -1.30 | -1.20 | -1.46 | -1.81 |
| Operating CF | 116.98M | 130.25M | 24.65M | 11.57M | (20.12M) | (53.05M) | (32.85M) | (18.69M) | (15.79M) | (17.95M) | (22.25M) |
| Total Assets | 907.32M | 808.38M | 676.81M | 564.88M | 295.08M | 281.19M | 181.25M | 200.08M | 25.09M | 13.12M | N/A |
| Total Debt | 32.16M | 31.79M | 24.85M | 16.41M | 34.09M | 30.63M | 25.35M | 24.93M | 16.46M | 15.69M | N/A |
| Cash & Equiv | 104.81M | 150.15M | 185.54M | 441.59M | 214.47M | 190.52M | 22.86M | 97.29M | 8.96M | 6.68M | N/A |
| Book Value | 781.16M | 689.70M | 572.51M | 496.01M | 229.05M | 229.75M | 139.84M | 164.00M | 1.48M | (6.61M) | N/A |
| Return on Equity | 0.19 | 0.08 | -0.04 | -0.09 | -0.18 | -0.25 | -0.24 | -0.13 | -11.80 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 204.58M | 269.08M | 224.50M | 217.09M | 201.32M | 239.72M | 203.19M | 195.88M | 164.01M | 192.51M | 153.30M | 151.09M |
| Net Income | (11.29M) | 136.09M | 9.93M | (3.59M) | 2.99M | 35.22M | 18.50M | 9.79M | (10.01M) | 14.76M | (8.54M) | (11.95M) |
| EPS | -0.39 | 4.70 | 0.34 | -0.12 | 0.10 | 1.18 | 0.62 | 0.33 | -0.34 | 0.50 | -0.29 | -0.41 |
| Free Cash Flow | 3.12M | 41.81M | 58.09M | (6.31M) | (15.11M) | 62.15M | 44.28M | (12.47M) | (2.84M) | 9.23M | (3.35M) | 237,000 |
| FCF / Share | 0.11 | 1.44 | 1.98 | -0.21 | -0.51 | 2.08 | 1.48 | -0.42 | -0.10 | 0.31 | -0.11 | 0.01 |
| Operating CF | 12.85M | 52.47M | 68.53M | 2.68M | (6.70M) | 69.18M | 52.28M | (78,000) | 8.86M | 17.27M | 3.64M | 5.09M |
| Total Assets | 911.38M | 918.49M | 807.72M | 802.19M | 730.81M | 808.38M | 796.19M | 728.39M | 685.84M | 676.81M | 639.49M | 618.25M |
| Total Debt | 29.55M | 62.15M | 32.58M | 33.06M | 33.52M | 31.79M | 25.33M | 24.51M | 24.50M | 24.85M | 25.17M | 23.37M |
| Cash & Equiv | 98.93M | 104.81M | 112.84M | 106.93M | 53.88M | 150.15M | 147.51M | 188.03M | 175.42M | 185.54M | 329.90M | 467.05M |
| Book Value | 792.34M | 781.16M | 666.46M | 677.81M | 635.74M | 689.70M | 696.56M | 638.07M | 589.02M | 572.51M | 544.18M | 529.36M |
| Return on Equity | -0.01 | 0.17 | 0.01 | -0.01 | 0.00 | 0.05 | 0.03 | 0.02 | -0.02 | 0.03 | -0.02 | -0.02 |
INSP News
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
INSP Highlights New OSA Data and PREDICTOR Study at SLEEP 2026
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
Alphatec vs. Inspire Medical Systems: Which Healthcare Stock Is a Better Buy in 2026?